Celldex Reports Second Quarter 2016 Results

Go back to Celldex Reports Second Quarter 2016 Results

Jefferies Raises Price Target on Celldex (CLDX) to $5 Following 2Q; Reiterates Hold

August 9, 2016 9:44 AM UTC

Jefferies reiterated a Hold rating on Celldex Therapeutics (NASDAQ: CLDX), and raised the price target to $5.00 (from $4.00), following the company's 2Q earnings report. Enrollment in the METRIC trial testing glemba in TNBC overexpressing gpNMB has been going slow. Management believes that... More

Celldex (CLDX) Tops Q2 EPS by 2c

August 8, 2016 4:11 PM UTC

Celldex (NASDAQ: CLDX) reported Q2 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $1.39 million versus the consensus estimate of $850 thousand.

For earnings history and earnings-related data on Celldex (CLDX) click here.

... More